CDKN2A and mantle cell lymphoma: Treatment of MCL cell lines with PRMT5 inhibitor-induced cell cycle arrest at the G1 phase in CDKN2A-deficient Z-138 and Maver-1 cells (Fig. 7b and Supplementary Fig. S5c).